Quality of life in patients with liver tumors treated with holmium-166 radioembolization

Roekel, Caren van; Smits, Maarten L. J.; Prince, Jip F.; Bruijnen, R.; Bosch, Maurice A.A.J. van den; Lam, Marnix G. E. H.

doi:10.1007/s10585-019-10006-1

Cited by 7 publications

(11 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment selection should be based on expected gain in survival AND adverse event profile. In our review on studies reporting quality of life after treatment with radioembolization, most included studies reported no significant change in quality of life (105). Our own study results are compliant with this finding:…”

Section: Discussionsupporting

confidence: 84%

“…although there was a decline in quality of life after one week, overall, quality of life was not significantly affected over time (105). Based on these findings in palliative patients, the impact of radioembolization on quality of life is limited.…”

Section: Discussionmentioning

confidence: 83%

“…show arterial enhancement or are well-defined. For those lesions, conventional RECIST criteria must be used (103,105). mRECIST could also be used for other hypervascular tumors, like neuro-endocrine neoplasms, however need to be validated in future studies.…”

Section: Mrecistmentioning

confidence: 99%

See 2 more Smart Citations

Personalized radioembolization for colorectal cancer patients with liver metastases

Roekel¹

View full text Add to dashboard Cite

Chapter 1 Introduction and outline Chapter 2 Radioembolization Chapter 3 Quality of life in patients with liver tumors treated with holmium-166 radioembolization Chapter 4 Evaluation of the safety and feasibility of same day 166 Ho-radioembolization simulation and treatment of hepatic metastases Chapter 5 Mode of progression after radioembolization in patients with colorectal cancer liver metastases Chapter 6 First evidence for a dose-response relationship in patients treated with 166 Ho-radioembolization: a prospective study Chapter 7 Dose-effect relationships of holmium-166 radioembolization in colorectal cancer Chapter 8 The efficacy of coil-embolization to obtain intrahepatic redistribution in radioembolization: qualitative and quantitative analyses Chapter 9 Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization -a prospective, within-patient randomized study Chapter 10 Discussion Chapter 11 Summary Chapter 12 Nederlandse samenvatting Chapter 13 Addenda Review Committee List of publications Dankwoord Biography General introduction 8 Chapter 1Although there are many treatment options for colorectal cancer patients with liver metastases, colorectal cancer still remains the second most common type of cancer death worldwide (1).There is a wide variety in colorectal cancer incidence rates: the disease can be considered a marker of socioeconomic development and is more prevalent in countries with a high human development index. In developing countries, such as Russia and China, there is an increase in both incidence and mortality.In long-term developed countries, such as the United Kingdom and Denmark, there is an increase in incidence but a decrease in mortality. In other countries, such as France and the United States, a decrease in both incidence and mortality is seen. The rises in incidence can be explained by a change in dietary patterns (processed meat and alcohol drinks) and lifestyle factors (a sedentary lifestyle), as well as a consequence of screening programs that lead to early detection. The decreases in mortality are due to improved treatment strategies in developed countries (1).The incidence rate increases with age, with the median age worldwide being 66 years. Although the incidence and mortality rates decline for almost all age groups, in high-income countries, they are increasing for individuals younger than 50 years. This is likely due to the change in diet and lifestyle over the past decades, which is first reflected in incidence rates in young age groups. In this patient group, most patients present with advanced-stage disease. For patients with distant-stage disease, the five-year survival rate is only 14% (2). The first site of metastasis is the liver and up to 30% of patients with colorectal cancer develops hepatic metastases (3). For these patients, improved treatment strategies are needed.One of these improved treatment strategies is radioembolization.Radioembolization is a treatment option for patients with primary or secondary liver tumors. The treat...

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Personalized radioembolization for colorectal cancer patients with liver metastases

Roekel¹

View full text Add to dashboard Cite

show abstract

“…No other variables had a significant influence on the development of GHS. 17 The development of quality of life after treatment was confirmed in the HEPAR PLUS study, again showing a significant decrease in quality of life early after treatment (i.e., 3 weeks) with rapid recovery thereafter. 12 Apart from a temporary significant decrease in the role functioning scale, only nonsignificant temporary decreases were noticed after 166 Ho-microsphere radioembolization.…”

Section: Quality Of Lifementioning

confidence: 79%

“…The European Organization for Research and Treatment of Cancer QLQ-C30 and LMC21 questionnaires were used to evaluate quality of life in the HEPAR and HEPAR II studies. 17 Measurements were performed at baseline, 1 week, 6 weeks, and at 6, 9, and 12 months after treatment. The course of the global health status and symptom and functioning scales were analyzed using a linear mixed model.…”

Section: Quality Of Lifementioning

confidence: 99%

Holmium-166 Radioembolization

Lam

Smits

Bruijnen

et al. 2021

Digestive Disease Interventions

Self Cite

View full text Add to dashboard Cite

Radioembolization is usually performed with microspheres containing yttrium-90 (90Y). Holmium-166 (166Ho)-microspheres were developed as an alternative new product for radioembolization. The unique characteristics of 166Ho-microspheres allow for improved imaging possibilities. They can be visualized and quantified, already at low numbers and activities, to predict treatment distribution using 166Ho-microspheres at scout quantity during pre-treatment simulation. The option to reliably predict the distribution of microspheres provides physicians control over the treatment, allowing them to select and treat patients with a personalized treatment plan. Safety and efficacy were established in several clinical studies. 166Ho-microspheres radioembolization aims to optimize individualized treatment planning in order to improve treatment outcomes.

show abstract

Holmium-166 Radioembolization of Hepatic Metastases in Salvage Setting: Preliminary Findings from a Single Center Experience

Dökdök,

Berberoğlu

2023

Journal of Clinical Interventional Radiology ISVIR

View full text Add to dashboard Cite

Purpose The aim of this study is to report the early outcomes of holmium-166 (166Ho) radioembolization in the treatment of liver metastases. Methods Nine patients with liver metastases originating from different primary sites were treated with 166Ho radioembolization between January 2019 and February 2020. The patients were assessed for pain using a visual analog scale (VAS) and quality of life (QoL) at various intervals during hospitalization and follow-up. Toxicity that may be attributable to radioembolization was graded according to CTCAE v5.0. The tumor dosimetry and tumor response were assessed with anatomic and metabolic imaging. Results The mean tumor dose was 150 Gy, 95% confidence interval (CI) was 135.2 to 164.8, with a range of 100 to 200 Gy based on single-photon emission computed tomography (SPECT)/CT, and distribution verified with inline T2/R2* magnetic resonance imaging (MRI) maps. No early (30-day) mortality or grade greater than 2 toxicities were noted, but one patient had chylous ascites. QoL assessed with the European Quality of Life 5-Dimensions 3-Level version (EQ-5D-3L) revealed mean index scores of 0.748 (range: 0.5–1), 95% CI of 0.6 to 0.9, before the procedure, and 0.7 (range: 0.5–1) and 95% CI of 0.6 to 0.8, at 1 month. The mean VAS was 70.6, 95% CI was 65.5 to 75.6, immediately after the procedure, and decreased to the mean VAS of 65.7 and 95% CI of 55.9 to 75.5 after 1 month. Five patients showed a partial response, three showed a stable disease, and one showed progressive disease at the first 2- to 3-month imaging follow-up. Conclusion Radioembolization with 166Ho microspheres for liver metastases appears to be safe, tolerable, and effective during the short term in this small-scale study.

show abstract

Quality of life in patients with liver tumors treated with holmium-166 radioembolization

Cited by 7 publications

References 36 publications

Personalized radioembolization for colorectal cancer patients with liver metastases

Personalized radioembolization for colorectal cancer patients with liver metastases

Holmium-166 Radioembolization

Holmium-166 Radioembolization of Hepatic Metastases in Salvage Setting: Preliminary Findings from a Single Center Experience

Contact Info

Product

Resources

About